




Searching News Database: Integrated BioPharma
HSMN NewsFeed - 8 Jul 2021
Elevar Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams
Elevar Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams
HSMN NewsFeed - 4 Sep 2020
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
HSMN NewsFeed - 29 Jul 2019
RenalytixAI Appoints Thomas McLain as President and Chief Commercial Officer
RenalytixAI Appoints Thomas McLain as President and Chief Commercial Officer
HSMN NewsFeed - 3 Jun 2019
Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
HSMN NewsFeed - 15 Apr 2019
Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion
Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion
HSMN NewsFeed - 21 Jul 2017
Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo(R) (Telotristat Ethyl)
Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo(R) (Telotristat Ethyl)
HSMN NewsFeed - 27 Jan 2017
Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
HSMN NewsFeed - 6 Jul 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
HSMN NewsFeed - 10 May 2016
Praveen Tyle, Ph.D. Joins Lexicon As Executive Vice President Of Research And Development
Praveen Tyle, Ph.D. Joins Lexicon As Executive Vice President Of Research And Development
HSMN NewsFeed - 5 Jan 2015
Catalyst Pharmaceuticals Appoints David D. Muth, Executive Vice President, Chief Commercial Officer
Catalyst Pharmaceuticals Appoints David D. Muth, Executive Vice President, Chief Commercial Officer
HSMN NewsFeed - 16 Jul 2014
MediWound Announces NexoBrid Marketing Approval From Israeli Ministry of Health
MediWound Announces NexoBrid Marketing Approval From Israeli Ministry of Health
HSMN NewsFeed - 8 May 2014
MediWound Expands Distribution of NexoBrid to Russia Through Agreement With Genfa Medica
MediWound Expands Distribution of NexoBrid to Russia Through Agreement With Genfa Medica
HSMN NewsFeed - 16 Apr 2014
Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
HSMN NewsFeed - 4 Mar 2014
ThromboGenics Initiates Major Post-Marketing Patient Trial with JETREA(R) in the US
ThromboGenics Initiates Major Post-Marketing Patient Trial with JETREA(R) in the US
HSMN NewsFeed - 4 Jan 2013
ThromboGenics Confirms JETREA(R) US Launch Date of Monday January 14th, 2013
ThromboGenics Confirms JETREA(R) US Launch Date of Monday January 14th, 2013
HSMN NewsFeed - 5 Apr 2012
Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP(R) (aflibercept)
Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP(R) (aflibercept)
HSMN NewsFeed - 18 Apr 2011
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
HSMN NewsFeed - 8 Apr 2011
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
HSMN NewsFeed - 14 Dec 2010
Human Genome Sciences Appoints Colin Goddard, Ph.D., to Its Board of Directors
Human Genome Sciences Appoints Colin Goddard, Ph.D., to Its Board of Directors
HSMN NewsFeed - 20 Jan 2010
Constellation Pharmaceuticals Appoints Industry Veteran Garen Bohlin to Senior Management Group
Constellation Pharmaceuticals Appoints Industry Veteran Garen Bohlin to Senior Management Group
HSMN NewsFeed - 30 Apr 2009
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
HSMN NewsFeed - 24 Mar 2008
Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage
Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage
HSMN NewsFeed - 18 Mar 2008
FDA issues Approvable Letter for ceftobiprole, a new anti-MRSA broad-spectrum antibiotic
FDA issues Approvable Letter for ceftobiprole, a new anti-MRSA broad-spectrum antibiotic
HSMN NewsFeed - 14 Nov 2007
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
HSMN NewsFeed - 16 Oct 2007
Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
HSMN NewsFeed - 20 Sep 2007
ImClone Systems Expands IMC-A12 Development with Ten New Planned Clinical Trials
ImClone Systems Expands IMC-A12 Development with Ten New Planned Clinical Trials
HSMN NewsFeed - 14 Sep 2007
Canadian Regulatory Authority has Accepted for Review New Drug Submission for Ceftobiprole
Canadian Regulatory Authority has Accepted for Review New Drug Submission for Ceftobiprole
HSMN NewsFeed - 11 Sep 2007
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
HSMN NewsFeed - 10 Sep 2007
ImClone Settles Patent Lawsuit and Gains Rights to Additional Intellectual Property
ImClone Settles Patent Lawsuit and Gains Rights to Additional Intellectual Property
HSMN NewsFeed - 27 Aug 2007
Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
HSMN NewsFeed - 9 Aug 2007
Newly Created Hemosol BioPharma Inc. on the Hunt for Partnership, Licensing and Acquisition Targets
Newly Created Hemosol BioPharma Inc. on the Hunt for Partnership, Licensing and Acquisition Targets
HSMN NewsFeed - 27 Jul 2007
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
HSMN NewsFeed - 12 Jul 2007
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
HSMN NewsFeed - 7 May 2007
OMRIX Biopharmaceuticals Submits Regulatory Filing for Hepatitis B Immunoglobulin (HBIG) in Sweden
OMRIX Biopharmaceuticals Submits Regulatory Filing for Hepatitis B Immunoglobulin (HBIG) in Sweden
HSMN NewsFeed - 26 Apr 2007
Lexicon Genetics Changes Name to Lexicon Pharmaceuticals as Drug Development Pipeline Progresses
Lexicon Genetics Changes Name to Lexicon Pharmaceuticals as Drug Development Pipeline Progresses
HSMN NewsFeed - 10 Apr 2007
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
HSMN NewsFeed - 4 Apr 2007
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
HSMN NewsFeed - 10 Jan 2007
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
HSMN NewsFeed - 6 Nov 2006
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
HSMN NewsFeed - 28 Sep 2006
ImClone Systems Promotes Ana I. Stancic to Senior Vice President, Finance
ImClone Systems Promotes Ana I. Stancic to Senior Vice President, Finance
HSMN NewsFeed - 27 Sep 2006
Avalon Pharmaceuticals Appoints David D. Muth to Executive Vice President, Chief Business Officer
Avalon Pharmaceuticals Appoints David D. Muth to Executive Vice President, Chief Business Officer
HSMN NewsFeed - 18 Sep 2006
ImClone Systems Issues Statement on Court Ruling in Litigation against Yeda
ImClone Systems Issues Statement on Court Ruling in Litigation against Yeda
HSMN NewsFeed - 22 Aug 2006
Prestwick Pharmaceuticals Appoints George F. Horner III as President and Chief Executive Officer
Prestwick Pharmaceuticals Appoints George F. Horner III as President and Chief Executive Officer
HSMN NewsFeed - 22 Aug 2006
Momenta Pharmaceuticals Announces Appointment of Craig A. Wheeler as Chief Executive Officer
Momenta Pharmaceuticals Announces Appointment of Craig A. Wheeler as Chief Executive Officer
HSMN NewsFeed - 10 Aug 2006
ImClone Systems Completes Review of Strategic Alternatives and Decides to Remain Independent
ImClone Systems Completes Review of Strategic Alternatives and Decides to Remain Independent
HSMN NewsFeed - 2 Aug 2006
ImClone Systems Promotes Michael P. Bailey to Senior Vice President, Commercial Operations
ImClone Systems Promotes Michael P. Bailey to Senior Vice President, Commercial Operations
HSMN NewsFeed - 16 May 2006
ImClone Systems Names Elizabeth Yamashita Vice President, Regulatory CMC and Operations
ImClone Systems Names Elizabeth Yamashita Vice President, Regulatory CMC and Operations
HSMN NewsFeed - 15 May 2006
ESBATech AG Announces Appointment of James Egan as Chief Business Officer
ESBATech AG Announces Appointment of James Egan as Chief Business Officer
HSMN NewsFeed - 25 Apr 2006
Abraxis BioScience to Acquire European and U.S. Compliant Manufacturing Complex from Pfizer
Abraxis BioScience to Acquire European and U.S. Compliant Manufacturing Complex from Pfizer
HSMN NewsFeed - 3 Apr 2006
ImClone Systems Announces Receipt of $250 Million Milestone Payment from Bristol-Myers Squibb
ImClone Systems Announces Receipt of $250 Million Milestone Payment from Bristol-Myers Squibb
HSMN NewsFeed - 6 Mar 2006
MannKind Initiates Two U.S. Pivotal Phase 3 Studies of Inhaled Technosphere(R) Insulin
MannKind Initiates Two U.S. Pivotal Phase 3 Studies of Inhaled Technosphere(R) Insulin
HSMN NewsFeed - 9 Feb 2006
ImClone Systems Promotes Richard Crowley to Senior Vice President, Biopharmaceutical Operations
ImClone Systems Promotes Richard Crowley to Senior Vice President, Biopharmaceutical Operations
HSMN NewsFeed - 1 Feb 2006
CuraGen and TopoTarget Initiate Phase II Clinical Trial of PXD101 for T-Cell Lymphoma
CuraGen and TopoTarget Initiate Phase II Clinical Trial of PXD101 for T-Cell Lymphoma
HSMN NewsFeed - 24 Jan 2006
ImClone Systems Engages Lazard to Review Strategic Alternatives for the Company
ImClone Systems Engages Lazard to Review Strategic Alternatives for the Company
Additional items found! 133

Members Archive contains
133 additional stories matching:
Integrated BioPharma
(Password required)
Integrated BioPharma
(Password required)